Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL911502

CN1C2CCCC1CC(Oc1cccc(Br)c1)C2.O=C(O)C(F)(F)F

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 7/20 0.54
SLC6A3 Q01959 3/20 0.50
SLC6A2 P23975 2/20 0.50
SLC6A4 P31645 2/20 0.46
CHRM2 P08172 1/20 0.45
CHRM1 P11229 1/20 0.45
CHRM3 P20309 1/20 0.45
KCNH2 Q12809 6/20 0.43
OPRM1 P35372 3/20 0.43
GPR6 P46095 1/20 0.42
LNPEP Q9UIQ6 1/20 0.42
KDM4E B2RXH2 2/20 0.40
HTR3E A5X5Y0 1/20 0.40
HTR3B O95264 1/20 0.40
CHRNA7 P36544 1/20 0.40
HTR3A P46098 1/20 0.40
HTR3D Q70Z44 1/20 0.40
HTR3C Q8WXA8 1/20 0.40
OPRD1 P41143 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL911501 1.00 OPRK1 (0.54) OPRK1SLC6A3SLC6A2SLC6A4CHRM2
SCHEMBL911692 0.88 SLC6A2 (0.59) OPRK1SLC6A3SLC6A2SLC6A4CHRM2
SCHEMBL911693 0.88 SLC6A2 (0.59) OPRK1SLC6A3SLC6A2SLC6A4CHRM2
Trifluoroacetic Acid SCHEMBL911957 0.85 OPRK1 (0.57) OPRK1SLC6A3SLC6A2SLC6A4KCNH2
Trifluoroacetic Acid SCHEMBL911959 0.85 OPRK1 (0.57) OPRK1SLC6A3SLC6A2SLC6A4KCNH2
SCHEMBL911503 0.75 OPRK1 (0.37) OPRK1SLC6A3SLC6A2SLC6A4KCNH2
SCHEMBL911193 0.75 SLC6A2 (0.87) OPRK1SLC6A3SLC6A2SLC6A4CHRM2
SCHEMBL911194 0.75 SLC6A2 (0.87) OPRK1SLC6A3SLC6A2SLC6A4CHRM2
Trifluoroacetic Acid SCHEMBL15476928 0.74 SLC6A3 (0.57) OPRK1SLC6A3SLC6A2SLC6A4CHRM2
Trifluoroacetic Acid SCHEMBL15476929 0.74 SLC6A3 (0.57) OPRK1SLC6A3SLC6A2SLC6A4CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868017-B2 9-azabicyclo[3.3.1]nonane derivatives N.V. ORGANON (NL) 2011-01-11 US disclosed
EP-1934212-A1 9-AZABICYCLO [3 . 3 . 1]NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS N.V. Organon (NL) 2008-06-25 EP disclosed
US-20070112019-A1 9-Azabicyclo[3.3.1]nonane derivatives N.V. ORGANON (NL) 2007-05-17 US disclosed
WO-2007039563-A1 9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS N.V. ORGANON (NL) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112019-A1 9-Azabicyclo[3.3.1]nonane derivatives AZI2, TPMT, TET3 OPRK1 3261/4885SLC6A3 339/4885SLC6A2 1059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.